Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.74 |
| ▸ | LAP3 | P28838 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027392 | 1.00 | LTA4H (0.74) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL2032141 | 1.00 | LTA4H (0.74) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| Hydrochloric Acid SCHEMBL4229807 | 0.98 | LTA4H (0.72) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL4701244 | 0.87 | LTA4H (0.74) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL29399745 | 0.85 | LTA4H (1.00) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL11216638 | 0.85 | LTA4H (0.72) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL1893279 | 0.85 | LTA4H (1.00) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL1893281 | 0.85 | LTA4H (1.00) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL13696737 | 0.85 | LTA4H (0.72) | LTA4HLAP3LMNACYP1A2PTGS1 | |
| SCHEMBL4243613 | 0.85 | LMNA (0.59) | LTA4HLAP3LMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20080267888-A1 | Heterocyclic Derivatives | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-10-30 | — | — | US | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| WO-2003014113-A1 | NOVEL BENZOPYRAN COMPOUNDS AND PROCESS FOR THEIR PREPARATION AND USE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2003-02-20 | — | — | WO | disclosed |
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| WO-2000006559-A1 | REDUCED DIPEPTIDE ANALOGUES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267888-A1 | Heterocyclic Derivatives | CYP11B2, MAPT, UGT1A1 | LTA4H 2081/4885LAP3 2197/4885LMNA 2549/4885 |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | LTA4H 31/4885LAP3 151/4885LMNA 1539/4885 |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | UGT2B7, CYP4B1, CYP1B1 | LTA4H 1061/4885LAP3 2630/4885LMNA 3630/4885 |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | LTA4H 2416/4885LAP3 1416/4885LMNA 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.